Ajanta Pharma Q3 Results: Net Profit Rises 11% to Rs 233 Crore
Ajanta Pharma has reported an 11% year-on-year increase in its consolidated profit after tax for the third quarter of fiscal year 2025 (Q3 FY25), ended December 31, 2024. The company's financial performance reflects steady growth in its operations.
Financial Performance Overview
For the quarter ended December 31, 2024, Ajanta Pharma reported a consolidated profit after tax of Rs 233 crore, up from Rs 210 crore in the same period of the previous fiscal year. Revenue from operations for Q3 FY25 stood at Rs 1,146 crore, compared to Rs 1,105 crore in the year-ago period.
Key Financial Highlights (Consolidated, YoY)
- Net Profit: Increased by 11% to Rs 233 crore from Rs 210 crore.
- Revenue from Operations: Stood at Rs 1,146 crore, compared to Rs 1,105 crore in the year-ago period.
Shares of Ajanta Pharma settled 1.64% higher at Rs 2,670.70 apiece on the BSE following the announcement of the results.
Ajanta Pharma's Q3 FY25 results demonstrate the company's continued growth momentum, with an 11% increase in net profit. The company's performance reflects its steady progress in the pharmaceutical industry.
Disclaimer: The views and investment tips expressed in this article are for informational purposes only and do not represent financial advice. The views expressed are those of the sources cited and not necessarily those of this website or its management. Investing in equities or other financial instruments carries the risk of financial loss. Readers must exercise due caution and conduct their own research before making any investment decisions. We are not liable for any losses incurred as a result of decisions made based on this article. Please consult a qualified financial advisor before making any investment.
0 comments:
Post a Comment